Evidence map›Paper›PMID 34507997›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Complement C5 inhibition protects against hemolytic anemia and acute kidney injury in anthrax peptidoglycan-induced sepsis in baboons.

Ravi Shankar Keshari, Narcis Ioan Popescu, Robert Silasi, Girija Regmi, Cristina Lupu, Joe H Simmons, Alonso Ricardo, K Mark Coggeshall, Florea Lupu

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ravi Shankar KeshariCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.ORCID 0000-0002-4177-9095
Narcis Ioan PopescuArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.ORCID 0000-0002-4809-9885
Robert SilasiCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.
Girija RegmiCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.ORCID 0000-0001-6827-3783
Cristina LupuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.ORCID 0000-0001-8619-0893
Joe H SimmonsMichale E. Keeling Center for Comparative Medicine and Research, University of Texas MD Anderson Cancer Center, Bastrop, TX 78602.ORCID 0000-0003-1815-6831
Alonso RicardoRa Pharmaceuticals Inc., Cambridge, MA 02140.
K Mark CoggeshallArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.ORCID 0000-0003-4797-9095
Florea LupuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104; florea-lupu@omrf.org.ORCID 0000-0003-1249-9278
Oklahoma Medical Research Foundation · USThe University of Texas MD Anderson Cancer Center · US

Funding

Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2004 to 2023
$56.2M
Specific Pathogen Free Baboon Research Resource (SPFBRR) - Bridge Funding Administrative SupplementP40OD024628 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Joe H. Simmons · 2017 to 2026
$15.7M
Pilot ProjectP30GM114731 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI MCEVER, RODGER PAUL · 2016 to 2020
$6.5M
Contact Activation and InfectionR01AI157037 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2020 to 2024
$3.3M
Coagulation and Complement Activation in SepsisR01GM121601 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI LUPU, FLOREA · 2017 to 2020
$1.6M
Viral miRs and cellular miRs in sepsisR01GM122775 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LUPU, FLOREA · 2018 to 2020
$1.1M
NIAID NIH HHS R01 AI157037NIAID NIH HHS U19 AI062629NIGMS NIH HHS P30 GM114731NIGMS NIH HHS R01 GM121601NIGMS NIH HHS R01 GM122775NIH HHS P40 OD024628
6 · The paper itself

Abstract

Late-stage anthrax infections are characterized by dysregulated immune responses and hematogenous spread of

Indexed as

Acute Kidney InjuryAnemia, HemolyticAnimalsAnthraxBacillus anthracisCell WallComplement C5FemaleHemolysisMalePapioPeptidoglycanSepsisComplement C5Peptidoglycanacute kidney injuryanthraxcomplementhemolysispeptidoglycan

Identifiers

PMID34507997
PMCPMC8449412
OpenAlexW3196428888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.